Literature DB >> 19375763

Evidence of proatherogenic inflammation in polycystic ovary syndrome.

Frank González1, Neal S Rote, Judi Minium, John P Kirwan.   

Abstract

Women with polycystic ovary syndrome (PCOS) have chronic low-level inflammation that can increase the risk of atherogenesis. We measured circulating proatherogenic inflammatory mediators in women with PCOS (8 lean: body mass index, 18-25 kg/m(2); 8 obese: body mass index, 30-40 kg/m(2)) and weight-matched controls (8 lean, 8 obese). Blood samples were obtained fasting and 2 hours after glucose ingestion to measure interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1), monocyte chemotactic protein-1 (MCP-1), C-reactive protein (CRP), matrix metalloproteinase-2, plasminogen activator inhibitor-1 (PAI-1), and activated nuclear factor kappaB in mononuclear cells. Truncal fat was determined by dual-energy x-ray absorptiometry. Fasting MCP-1 levels were elevated in lean women with PCOS compared with lean controls (159.9 +/- 14.1 vs 121.2 +/- 5.4 pg/mL, P < .02). Hyperglycemia failed to suppress matrix metalloproteinase-2 in lean women with PCOS compared with lean controls (1.7 +/- 1.2 vs -4.8 +/- 1.6 pg/mL, P < .002). Among women with PCOS, obese individuals exhibited higher fasting sICAM-1 (16.1 +/- 0.8 vs 10.5 +/- 1.0 ng/mL, P < .03) and PAI-1 (6.1 +/- 0.7 vs 3.4 +/- 0.8 ng/mL, P < .03) levels. Trend analysis revealed higher (P < .005) IL-6, sICAM-1, CRP, PAI-1, systolic and diastolic blood pressures, triglycerides, fasting insulin, and homeostasis model assessment of insulin resistance index in women with PCOS compared with weight-matched controls, and the highest levels in the obese regardless of PCOS status. Fasting MCP-1 levels correlated with activated nuclear factor kappaB during hyperglycemia (P < .05) and androstenedione (P < .004). Truncal fat correlated with fasting IL-6 (P < .004), sICAM-1 (P < .006), CRP (P < .0009), and PAI-1 (P < .02). We conclude that both PCOS and obesity contribute to a proatherogenic state; but in women with PCOS, abdominal adiposity and hyperandrogenism may exacerbate the risk of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375763      PMCID: PMC2737595          DOI: 10.1016/j.metabol.2009.02.022

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  50 in total

1.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

Authors:  N C Andrews; D V Faller
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

3.  Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples.

Authors:  M Modan; M I Harris; H Halkin
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

4.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

5.  Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.

Authors:  Lourdes Ibáñez; Francis de Zegher
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

6.  Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.

Authors:  Lourdes Ibáñez; Francis De Zegher
Journal:  Hum Reprod       Date:  2004-06-30       Impact factor: 6.918

7.  Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.

Authors:  G A Burghen; J R Givens; A E Kitabchi
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

8.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

9.  Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease.

Authors:  N Boulman; Y Levy; R Leiba; S Shachar; R Linn; O Zinder; Z Blumenfeld
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  Insulin resistance in aging is related to abdominal obesity.

Authors:  W M Kohrt; J P Kirwan; M A Staten; R E Bourey; D S King; J O Holloszy
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

View more
  34 in total

Review 1.  Identification and treatment of metabolic complications in pediatric obesity.

Authors:  Katie Larson Ode; Brigitte I Frohnert; Brandon M Nathan
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

2.  Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line.

Authors:  Shaletha Holmes; Meharvan Singh; Chang Su; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2016-05-11       Impact factor: 4.736

3.  Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.

Authors:  Paulina A Essah; James A Arrowood; Kai I Cheang; Swati S Adawadkar; Dale W Stovall; John E Nestler
Journal:  Fertil Steril       Date:  2011-07-05       Impact factor: 7.329

4.  Evidence of mononuclear cell preactivation in the fasting state in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Obstet Gynecol       Date:  2014-06-20       Impact factor: 8.661

Review 5.  The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Elisabet Stener-Victorin; XiaoKe Wu; Richard S Legro
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

6.  Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.

Authors:  Shannon A Morrison; Amy M Goss; Ricardo Azziz; Dheeraj A Raju; Barbara A Gower
Journal:  Hum Reprod       Date:  2016-11-08       Impact factor: 6.918

7.  Serum tumor necrosis factor-α, interleukin-6, monocyte chemotactic protein-1 and paraoxonase-1 profiles in women with endometriosis, PCOS, or unexplained infertility.

Authors:  Abdelmoneim Younis; Kristina Hawkins; Halleh Mahini; William Butler; Mahdi Garelnabi
Journal:  J Assist Reprod Genet       Date:  2014-09-04       Impact factor: 3.412

8.  Hepatic steatosis in overweight/obese females: new screening method for those at risk.

Authors:  Giovanni Tarantino; Genoveffa Pizza; Annamaria Colao; Fabrizio Pasanisi; Paolo Conca; Patrizia Colicchio; Carmine Finelli; Franco Contaldo; Carolina Di Somma; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

9.  Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

10.  Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Agnieszka Nikolajuk; Irina Kowalska; Monika Karczewska-Kupczewska; Agnieszka Adamska; Elzbieta Otziomek; Slawomir Wolczynski; Ida Kinalska; Maria Gorska; Marek Straczkowski
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.